Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Open Posterior Thoracolumbar Spinal Fusion Procedure
Interventions: Tranexamic Acid Injectable Product (1000 mg intravenous bolus), Vitamin C 250 MG Oral Tablet, Tranexamic Acid 650Mg Tablet; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis
Interventions: High-Intensity Treadmill Training, Treadmill Training with Perturbations, Standard Treadmill Training; Procedure
Lead sponsor: Marquette University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Indianapolis, Indiana • Milwaukee, Wisconsin

Conditions: Comorbidity, Self-Management
Interventions: Health Coach Intervention; Behavioral
Lead sponsor: Clinical Directors Network; Network
Eligibility: 18 Years and older
Enrollment: 1,920 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 4
States / cities: Chicago, Illinois • Brooklyn, New York • New York, New York

Conditions: Ovarian Cancer, Breast Cancer
Interventions: Questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • New York, New York + 1 more

Conditions: Postoperative Cognitive Complications, Delirium, Perioperative/Postoperative Complications, Brain Injuries, Anesthesia
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions: Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 40
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Smoldering Plasma Cell Myeloma
Interventions: Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration; Biological · Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 742
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more

Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia
Interventions: Unmanipulated UCB, SR-1 UCB; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 2 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 634
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more

Conditions: Brain Neoplasm, Lymphoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
Interventions: Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer
Interventions: N-803 and BCG, N-803; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 28
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Drinking Behavior
Interventions: Social media messaging; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 25 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy; Drug · Genetic · Other + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 1 Year to 25 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary
Interventions: VITALYST System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts • New York, New York

Conditions: Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
Interventions: Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for ALLO Transplant); Radiation · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
Interventions: exercise intervention, counseling intervention, Educational Intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Fitness testing; Behavioral · Other · Procedure
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 3
States / cities: Detroit, Michigan • Lebanon, New Hampshire • Chapel Hill, North Carolina

Conditions: Breast Reconstruction, Perfusion; Complications, High Risk for Breast Cancer, Genetic Predisposition
Interventions: Minoxidil, Hair mousse; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Filgrastim, Genetically Engineered Lymphocyte Therapy, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Plerixafor, Rituximab; Procedure · Biological · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: COVID-19, Cancer
Interventions: Telehealth; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension, Stroke
Interventions: Text messaging; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Decompensated Heart Failure
Interventions: Spironolactone and patiromer; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome
Interventions: interferon beta 1a 30 ug IM once weekly; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 20
States / cities: Derby, Connecticut • Tampa, Florida • Atlanta, Georgia + 16 more

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions: amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC); Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 1 Year to 45 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prostate Cancer
Interventions: bicalutamide, goserelin acetate, assessment of therapy complications, quality-of-life assessment, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis

Preventing Tipping Points in High Comorbidity Patients: A Lifeline From Health Coaches

Lynne Cohen Consortium Project: Multi-Center Database/Registry

Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

A Social Media Intervention for Risky Drinking

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19

REACH OUT: to Reduce High Blood Pressure in the Emergency Department

High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer